ArticleAbdominal radiology (New York)2026
The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effectiveness and safety of ultrasound (US)-guided percutaneous radiofrequency ablation (PRFA) for sub-cardiac hepatic tumors and evaluate the factors influencing local tumor progression (LTP).
methodsBetween January 2016 and January 2023, we included 118 patients (118 lesions) of US-guided RFA for sub-cardiac hepatic tumors (located in S2 or S4a, with a gap between the tumor and the left diaphragm ≤ 10 mm). We retrospectively analyzed patients' electronic medical records and imaging follow-up data to evaluate the success rate, LTP, and complications. We also used univariate and multivariate Cox regression to explore the risk factors for LTP.
resultsThe primary technical success rate for treating sub-cardiac hepatic tumors was 113/118 (95.8%). The success rate after the second ablation was 118/118 (100%). A single serious complication was recorded 1/118(0.8%), including acute pericardial tamponade and sudden cardiac arrest. The median follow-up period was 24 months (range, 1.2-72 months), with LTP occurring in 19 lesions (16.1%). Besides, the 1-year, 2-year, and 3-year cumulative rates of LTP were 12.7%, 15.3%, and 16.1%, respectively. Tumor size was an independent risk factor for LTP following ablation of sub-cardiac hepatic tumors (HR 1.06; 95% CI 1.02-1.11; P = 0.008). A larger minimal ablative margin (MAM) was associated with a lower hazard of LTP (HR 0.78; 95% CI 0.65-0.92; Wald P = 0.004; LR P = 0.002). Stratified analysis indicated that lesions ≥ 30 mm in diameter carried a significantly higher risk of LTP (HR 4.35; 95% CI 1.46-12.99; P = 0.009).
conclusionsUS-guided PRFA for sub-cardiac hepatic tumors is effective and safe, though caution is advised for tumors ≥ 30 mm due to a significantly higher LTP risk.
Indexed as
Identifiers
42043537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.